Login to Your Account

Orphan drug approvals are rising, but so are costs to patients

By Marie Powers
Staff Writer

Tuesday, July 15, 2014

Although approvals for orphan drugs have increased at a blistering pace in the U.S. and Europe, the cost of those drugs represents a growing challenge for patients and payers, according to a study conducted by the Center for the Study of Drug Development (CSDD) at Tufts University.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription